Cancer feature: cnaPANCAN2

ABCA7 ABHD17A ADAMTSL5 ADAT3 AMH AP3D1 APC2 ARID3A ATP5D ATP8B3 AZU1 BSG BTBD2 C19orf24 C19orf25 C19orf26 C19orf35 C2CD4C CDC34 CFD CIRBP CNN2 CSNK1G2 DAZAP1 DOT1L EFNA2 ELANE FGF22 FSTL3 GAMT GPX4 GRIN3B GZMM HCN2 HMHA1 IZUMO4 JSRP1 KISS1R KLF16 LINGO3 LMNB2 LPPR3 LSM7 MADCAM1 MBD3 MED16 MEX3D MIDN MIER2 MISP MKNK2 MOB3A MUM1 NDUFS7 OAZ1 ODF3L2 ONECUT3 PALM PCSK4 PLEKHJ1 PLK5 POLR2E POLRMT PPAP2C PRSS57 PRTN3 PTBP1 R3HDM4 REEP6 REXO1 RNF126 RPS15 SBNO2 SCAMP4 SF3A2 SHC2 STK11 TCF3 THEG TIMM13 TMEM259 TMPRSS9 TPGS1 UQCR11 UQCR11 WDR18

Known Driver Genes: STK11

Copy number alternation: loss

Bicalutamide

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer